Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Meclozine

Hazard - P - B - T - Risk See below

Information

Concentrations of meclozine in the environment are considered to be accumulated in fish to therapeutic levels. However, meclozine has not yet been found in fish. Effect studies are missing.

Meclozine is included in the Stockholm County Council's table of pharmaceuticals with risk for negative environmental impact according to the environmental program 2017–2021.  Meclozine has been detected in treated wastewater in Stockholm County in the last five years (2012–2016).

Is recommended in The Wise list. Environmental classification of pharmaceuticals is taken into consideration, sometimes with other environmental aspects, when selecting pharmaceuticals for the Wise list. When comparable pharmaceuticals are equivalent to medical effects, safety and pharmaceutical efficacy, environmental impact and price are considered.

Suggestions on how to reduce the release of meclozine

Concrete proposals on how to work to reduce emissions of environmentally harmful pharmaceuticals on the list have been developed in close cooperation with the Stockholm Drug and Therapeutics Committee's expert advice. The action proposals were developed from an environmental perspective. The patient's best always goes first and several pharmaceuticals on the list are also included in the Wise list. However, for such pharmaceuticals, there may be measures that could reduce the environmental impact.

Concrete proposal for meclozine

  • Meclozine (Postafen) is recommended in the Wise list.
  • An OTC package of 10 tablets is available but not included in the reimbursement system. This package is recommended whenever possible. In addition, there is a pack of 100 tablets available within the reimbursement system.

Environmental information for the substance is not available on fass.se. It is voluntary for manufacturers to publish environmental impact information on fass.se.

In The Wise list substances with little or moderate environmental impact are recommended before substances that are completely missing or have incomplete environmental data if the substances are medically equivalent.

References

  1. Goodpoint. Prioritering av läkemedel med miljörisk inom SLL. Stockholm: Goodpoint; 2016. Rapport LS 2016–0634.
  2. Fick J, Lindberg RH, Tysklind M, Larsson DG. Predicted critical environmental concentrations for 500 pharmaceuticals. Regul Toxicol Pharmacol. 2010;58:516-23.
  3. SLL. Sammanställning av läkemedelsprovtagningar - Bearbetning av regional försäljningsstatistik av läkemedel samt datamaterial från Stockholms läns landstings mätprogram för läkemedelssubstanser i vattenmiljö, 2012–2016.
  4. Stockholms läns landsting. Förteckning över miljöbelastande läkemedel med åtgärdsförslag framtagen inom ramen för SLL:s miljöprogram 2017–2021.
  5. Stockholms läns landsting. Kloka listan (Wise list).

Author: The Pharmaceutical unit of Region Stockholm